



Press release from Emotra AB (publ)  
Göteborg, August 13, 2014

## Symposium about EDOR at the EPA's international convention

**The European Psychiatric Association has decided which subjects are going to be highlighted at special symposiums at the "23rd European Congress of Psychiatry", which will take place on March 28–31, 2015, in Vienna, Austria. Emotra's method for evaluating suicide risk has been chosen as one of only three subjects. This convention is one of the world's largest psychiatric conventions and the most important international, annual one for European psychiatrists.**

This spring, Professor Marco Sarchiapone, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, and Emotra's scientific advisor, submitted an application to the Scientific Committee of the 2015 EPA Congress in Vienna to arrange a symposium about EDOR at the convention. Emotra's method, and two other subjects, were chosen in stiff competition with many other applicants. The fact that EDOR is being discussed in such an important context is a significant milestone for Emotra in our efforts to establish the method in the psychiatric care sector.

The EPA's decision shows that interest in Emotra's method for testing patients' suicide risk is growing among practising psychiatrists, but, and just as importantly, it is also proof of the value of the Company's agreement with the EPA's suicide section. If it had not been for the organisation's and professor Sarchiapone's direct involvement, EDOR would not have been chosen as the subject for a symposium as early as 2015.

EDOR will also be in the spotlight at several other important international conventions in the near future. A special symposium titled *Assessment of suicide risk: From research to clinical practice* chaired by Professor Marco Sarchiapone and Lars-Håkan Thorell will be held at the *15th European Symposium on Suicide*, August 27–30, 2014, in Tallinn, Estonia. Lars-Håkan Thorell will also be speaking at this symposium and presenting his research.

Lars-Håkan Thorell will also be speaking at the XVI World Congress of Psychiatry, being held on September 14–18 in Madrid. This convention is the World Psychiatric Association's annual international convention. On top of the above mentioned symposiums and presentations, Thorell and several other prominent opinion-leaders in the field will be presenting Emotra's method at various international and national conventions during 2014 and 2015.

**For further information, please contact:**

*Claes Holmberg, CEO*  
*Telephone: +46 708 25 45 47*  
*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

**Emotra AB** is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. *Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*